The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
EHA2023 abstracts: What’s hot in AML?
To help navigate the exciting content being presented at the European Hematology Association (EHA) 2023 Congress, the AML Hub Steering Committee have provided their recommendations of the top abstracts to look for.
Friday, June 9
Saturday, June 20
|
Abstract |
Type |
Title |
Presenter |
|
S248 |
Oral presentation |
SIERRA trial results with a targeted radiotherapy, Iomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active R/R AML |
Boglarka Gyurkocza |
|
S310 |
Oral presentation |
Keith Pratz |
Sunday, June 11
|
Abstract |
Type |
Title |
Presenter |
|
LB2711 |
Late breaking oral presentation |
BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML |
— |
|
LB2713 |
Late breaking oral presentation |
Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1- mutated AML |
— |
|
S137 |
Oral presentation |
Impact of allogeneic hematopoietic cell transplantation in first complete remission plus FLT3 inhibition with quizartinib in acute myeloid leukemia with FLT3-ITD: results from QuANTUM-First |
Richard Schlenk |
|
S138 |
Oral presentation |
Validation of the revised 2022 European LeukemiaNet (ELN) risk stratification in adult patients with acute myeloid leukemia |
Marius Bill |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content